Publication at First Faculty of Medicine |
2014
Abstract
A double-blind, randomized GALA study tested the effectiveness of th treatment of multiple sclerosis with glatiramer acetate (GA) subcutaneously at a dose 40 mg 3 times a week for 12 moths compared with placebo. A total ofd 1404 patients were randomized in a ratio of 2 : 1.
The relative reduction in the risk of relapse in patients trteated with GA reached 34% (risk ratio 0,656; CI 0,639 to 0,799); p<0,0001. EDSS progersssion for one year of the study did not differ significantly between the groups.